By Justin Petrone

ExonHit Therapeutics hopes to commercialize a microarray-based clinical test for diagnosing Alzheimer's disease in Europe by the first quarter of next year, the company said this week.

It is also in discussions with the US Food and Administration about the best way to submit the in vitro diagnostic for a possible 2012 launch, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

Vox explores a proposal to institute a lottery system to award grant funds.

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.